Global Carcinoembryonic Antigen (CEA) Market, By Test type (Molecular Tests, Serology Tests), Product Types (CD66a, CD66b, CD66c, CD66d, CD66e, CD66f), Gender (Male, Female), Application (Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, Thyroid Cancer, Ovarian Cancer, Others), End-User (Hospitals, Diagnostic Centers, Cancer Centers, Research, Academic Institutes) – Industry Trends and Forecast to 2029.
Carcinoembryonic Antigen (CEA) Market????? Analysis and Size
Carcinoembryonic antigen sensitivity is low in patients with early colon cancer. The carcinoembryonic antigen (CEA) test is particularly useful for rectum and large intestine cancers. Carcinoembryonic antigen is one of the most widely used tumour markers in the world. However, it is most important in colorectal cancer.
Data Bridge Market Research analyses that the carcinoembryonic antigen (CEA) market which was USD 1,855.41 million in 2021, is expected to reach USD 2,912.90 million by 2029, at a CAGR of 5.80% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Carcinoembryonic Antigen (CEA) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Test type (Molecular Tests, Serology Tests), Product Types (CD66a, CD66b, CD66c, CD66d, CD66e, CD66f), Gender (Male, Female), Application (Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Lung Cancer, Thyroid Cancer, Ovarian Cancer, Others), End-User (Hospitals, Diagnostic Centers, Cancer Centers, Research, Academic Institutes)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Quest Diagnostics Incorporated (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Genway Biotech, LLC. (U.S.), Abbott (U.S.), Mayo Foundation for Medical Education and Research (MFMER) (U.S.), Lee BioSolutions (U.S.), RayBiotech Life, Inc (U.S.), Correlogic Systems, Inc. (Hong Kong), Boster Biological Technology (U.S.), Omega Diagnostics Group PLC (U.K.), Creative Diagnostics (U.S.), Cigna (U.S.), Merck KGaA (Germany), Prospec-Tany Technogene Ltd (Israel), Laboratory Corporation of America Holdings (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Carcinoembryonic antigen (CEA) is found in embryonic endodermal epithelial cells. Carcinoembryonic antigen is a glycoprotein found in the fluids of the foetus and embryo, as well as the gastrointestinal tract. Carcinoembryonic antigen is also found in colorectal mucosal cells, gastrointestinal cells, and in trace amounts in the blood. The test is also to manage and diagnose cancers such as breast cancer, colorectal or colon cancer, gastrointestinal cancer, liver cancer, ovarian cancer, lung cancer, and others.
Global Carcinoembryonic Antigen (CEA) Market Dynamics
Drivers
- Rising awareness to bolster the growth
Increasing awareness about preclinical testing for disease detection, but carcinoembryonic antigen is the most cost-effective valuation, which continues to drive market demand for testing. Furthermore, consumers' rising disposable income, combined with rising life expectancy, will eventually result in market growth. Favourable government policies relating to cancer awareness and control implemented by organisations such as the National Cancer Institute and (CPCRN) are boost market growth.
- Technological developments
Proteomics-related technological advancements, such as protein bioinformatics, mass spectroscopy, protein labelling, imaging, and array-based approaches, are drive market growth. The development of new biomarkers and immunological techniques such as radioimmunoassay that can be used in conjunction with carcinoembryonic antigen (CEA) for the detection of various types of cancers will also drive market growth. For instance, the development of tumour markers that can be used in conjunction with CEA to detect colorectal cancer. Government initiatives to introduce new diagnostic tools/technologies are drive market growth. Furthermore, rising demand for minimally invasive diagnostic procedures to avoid various post-procedural side effects drives the growth of this market.
- Increasing number of cancer cases
According to the World Health Organization, cancer is one of the leading causes of death worldwide. It is expected to cause 10 million deaths by 2020. Cancer is responsible for approximately one in every six deaths worldwide. Cancer kills approximately 70% of people in low- and middle-income countries; the most common types of cancer are breast (2.26 million cases in 2020), lung (2.21 million cases in 2020), and colon and rectum cancers (1.93 million cases in 2020). The number of cancer cases diagnosed each year in the world has increased dramatically due to increased life expectancy, resulting in millions of people being diagnosed in their lifetime, driving the market's growth.
Opportunities
- Rise in the number of hospitals in the developing economies
Cancer has become the leading cause of death in many parts of the world due to rapid growth in the number of cancer patients and cancer incidences in both developed and developing countries. According to the WHO, nearly 10 million deaths occur each year as a result of cancer, with 1.93 million cases of colon and rectum cancer in 2020. Healthcare services are improving and focusing on earlier disease detection and treatment. Population growth and increased life expectancy are the primary factors driving the overall increase in incidence. Furthermore, rising public awareness of cancer has increased the number of patients who undergo screening.
- Increasing prevalence of unhealthy lifestyles
The increasing prevalence of unhealthy lifestyles such as irregular dietary habits and exposure to carcinogenic elements all contribute to its large share. Furthermore, increased alcohol consumption and sedentary lifestyle may contribute to the growth of colorectal cancer over the next seven years.
Restraints/Challenges
- Risk of infection will restrain the growth
Dearth of awareness about the carcinoembryonic antigen test, risk of infections by carcinoembryonic antigen testing and failure to detect cancer at the initial stage will obstruct the market's growth rate.
This carcinoembryonic antigen (CEA) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the carcinoembryonic antigen (CEA) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Carcinoembryonic Antigen (CEA) Market
COVID-19 has created new opportunities in the carcinoembryonic antigen (CEA) market. For instance, COVID-19 has forced us to concentrate on biotechnologically modified products in order to achieve better results. During the outbreak, many biopharmaceutical companies developed biotechnologically modified vaccines and diagnostic kits to treat SARS-CoV-2. Furthermore, biotechnological equipment has aided in various stages of the pandemic's combat; the COVID-19 pandemic has made us realise that biotechnological solutions provide a better healthcare system, positively affecting the Carcinoembryonic antigen (CEA) market.
Global Carcinoembryonic Antigen (CEA) Market Scope
The carcinoembryonic antigen (CEA) market is segmented on the basis of test type, product types, gender, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market.
Test Type
- Molecular Tests
- Serology Tests
Product Types
- CD66a
- CD66b
- CD66c
- CD66d
- CD66e
- CD66f
Gender
- Male
- Female
Application
- Gastrointestinal Cancer
- Colon Cancer
- Pancreatic Cancer
- Rectal Cancer
- Liver Cancer
- Stomach Cancer
- Esophageal Cancer
- Gallbladder Cancer
- Anal Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer
- Lung Cancer
- Thyroid Cancer
- Ovarian Cancer
- Others
End-User
- Hospitals
- Diagnostic Centers
- Cancer Centers
- Research
- Academic Institutes
Carcinoembryonic Antigen (CEA) Market Regional Analysis/Insights
The carcinoembryonic antigen (CEA) market is analysed and market size insights and trends are provided by country, test type, product types, gender, application and end user as referenced above.
The countries covered in the carcinoembryonic antigen (CEA) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the carcinoembryonic antigen (CEA) market due to the high incidence rates of cancer, presence of sophisticated healthcare infrastructure, and high patient awareness levels in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 owing to the growing awareness in patients, high incidence rates of cancer and existence of advanced healthcare framework in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The carcinoembryonic antigen (CEA) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for carcinoembryonic antigen (CEA) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the carcinoembryonic antigen (CEA) market. The data is available for historic period 2010-2020.
Competitive Landscape and Carcinoembryonic Antigen (CEA) Market Share Analysis
The carcinoembryonic antigen (CEA) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to carcinoembryonic antigen (CEA) market.
Some of the major players operating in the carcinoembryonic antigen (CEA) market are:
- Quest Diagnostics Incorporated (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Genway Biotech, LLC. (U.S.)
- Abbott (U.S.)
- Mayo Foundation for Medical Education and Research (MFMER) (U.S.)
- Lee BioSolutions (U.S.)
- RayBiotech Life, Inc (U.S.)
- Correlogic Systems, Inc. (Hong Kong)
- Boster Biological Technology (U.S.)
- Omega Diagnostics Group PLC (U.K.)
- Creative Diagnostics (U.S.)
- Cigna (U.S.)
- Merck KGaA (Germany)
- Prospec-Tany Technogene Ltd (Israel)
- Laboratory Corporation of America Holdings (U.S.)
SKU-